Karyopharm Therapeutics Files 8-K on Feb 16 Event
Ticker: KPTI · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, disclosure
TL;DR
**Karyopharm Therapeutics just filed an 8-K for an event on Feb 16, signaling important company news is coming.**
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing is a 'Current Report' under Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, incorporated in Delaware with IRS Employer Identification No. 26-3931704, maintains its principal executive offices at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
Why It Matters
This 8-K filing indicates a significant event for Karyopharm Therapeutics, requiring public disclosure to inform investors and maintain transparency.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not inherently indicate a positive or negative event without further context.
Key Numbers
- 001-36167 — Commission File Number (SEC identification for Karyopharm Therapeutics Inc.)
- 26-3931704 — IRS Employer Identification No. (Tax identification for Karyopharm Therapeutics Inc.)
- 617-658-0600 — Business Phone Number (Contact number for Karyopharm Therapeutics Inc.)
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- February 16, 2024 (date) — Date of earliest event reported
- February 20, 2024 (date) — Filed as of date
- Delaware (company) — State of Incorporation
- 001-36167 (dollar_amount) — Commission File Number
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Karyopharm Therapeutics Inc.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 16, 2024.
Where are Karyopharm Therapeutics Inc.'s principal executive offices located?
Karyopharm Therapeutics Inc.'s principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
What is the Commission File Number for Karyopharm Therapeutics Inc.?
The Commission File Number for Karyopharm Therapeutics Inc. is 001-36167.
Under which sections of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-02-20 08:00:57
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
- $1.00 — its common stock had failed to meet the $1.00 per share minimum bid price requirement
Filing Documents
- d774101d8k.htm (8-K) — 23KB
- 0001193125-24-039387.txt ( ) — 141KB
- kpti-20240216.xsd (EX-101.SCH) — 3KB
- kpti-20240216_lab.xml (EX-101.LAB) — 18KB
- kpti-20240216_pre.xml (EX-101.PRE) — 11KB
- d774101d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: February 20, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary